Divi's Laboratories Ltd.

DIVISLAB

₹4790.6

5.36% (243.6)

Market Cap

₹1,27,217 Cr.

P/E

79.51

About

Divi's Laboratories Limited is a key player in the pharmaceutical industry, specializing in the production of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceutical ingredients. Th… Read more

Divi's Laboratories Limited is a key player in the pharmaceutical industry, specializing in th… Read more

Low

3295

52W Range

High

4810

Quick View

CHART MODE

Price

CHART MODE

EV/EBITDA

Price to Sales

Price to Book

CHART MODE

Capex

CHART MODE

Debt

Company Timeline

Subscribe now for more updates

Forensics

8 Yes

Positive for this company

1 Neutral

Neutral for this company

8 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE

Latest

11.79%

3yr Average

17.11%

5yr Average

18.3%

Net Profit Margin

Latest

20.4%

3yr Average

25.64%

5yr Average

26.18%

ROCE

Latest

15.28%

3yr Average

21.12%

5yr Average

23.0%

Debt to Equity

Latest

3yr Average

0.0

5yr Average

0.0

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Brand Wise Break-Up

Asset Break-Up

Operational Metrics

R&D as a % of Total Sales (%)
Source

Peer Comparison

Suppliers

Neogen Chemicals Ltd.
HLE Glascoat Ltd.
Tatva Chintan Pharma Chem Ltd.

FAQs on Divi's Laboratories Ltd. Business

What does Divi's Lab do?

Divi's Laboratories Limited is a global pharmaceutical company specializing in the manufacturing of API's, Intermediates, and Nutraceutical ingredients for exports. It also offers custom synthesis services to innovator pharma companies for their patented products.

Who are the competitors of Divi's Lab?

Divi's Lab major competitors are Laurus Labs, Granules India, Neuland Laboratories, Glenmark Life Scienc, Shilpa Medicare, Aarti Pharmalabs, AMI Organics.
Market Cap of Divi's Lab is ₹1,27,217 Crs.
While the median market cap of its peers are ₹10,423 Crs.

Is Divi's Lab financially stable compared to its peers?

Divi's Lab seems to be financially stable compared to its peers.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate peers.

Company Filing

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	Jun Mar	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by OpenAI	Jun			Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec